Volunteers will receive two doses of the vaccine, and don't need to be hospitalized during the trial period.
India's first vaccine candidate against the novel coronavirus, COVAXIN, has received a nod from the Drug Controller General of India (DCGI) for further clinical trials Phase I and 2 in infected people.
Media captionCoronavirus: What is a vaccine and how is one made?
In the past, Bharat Biotech has developed vero cell culture platform technologies, which have been helpful in several vaccines for polio, rabies, rotavirus, Japanese encephalitis, chikungunya, and Zika.
"From July 2020, the safety of the vaccine will be extensively tested in a small cohort of human volunteers".
The Phase 1 and 2 clinical trials of the CanSino's vaccine candidate showed it has the potential to prevent diseases caused by the coronavirus, which has killed half a million people globally, but its commercial success can not be guaranteed, the company said. "The proactive support and guidance from CDSCO have enabled approvals.[and] Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform (sic)".
Most experts think a coronavirus vaccine is likely to become available by mid-2021, about 12-18 months after the new virus, known officially as Sars-CoV-2, first emerged.
Vaccine testing typically begins with animal and lab testing before going on to different stages of human testing.
No vaccine has yet been approved for commercial use against the illness caused by the new coronavirus, but over a dozen vaccines from more than a 100 candidates globally are being tested in humans. Since January, J&J has been working directly with governments and health authorities to help end this fast-moving COVID-19 pandemic.
A vaccine is widely acknowledged as the key to ending the pandemic, and will provide enormous benefits for the country that gets there first.
"The difference between the strains present globally is something still being researched", a spokesperson for the vaccine maker told the BBC. But for the U.S. or China, it would also be a massive geopolitical victory. Their candidate is now in pre-clinical studies.
Now, with DGCI's approval, the Phase-1 and Phase-2 clinical trial of COVAXIN will begin across the country in July (although the exact dates are not clear).
India is among the largest manufacturer of generic drugs and vaccines in the world.
But vaccines against viruses are extremely hard to develop, and a "gold standard" preventor - one that lasts six months, is at least 50 per cent effective and can successfully prevent transmission of the virus - will no doubt take time.